

2413F PCT

BEST AVAILABLE COPY

SUMMARY

This invention is related to the use of the compound formed by sodium hyaluronate and sodium chondroitin sulfate for the treatment of chondral lesions in osteoarthritis. This invention is particularly addressed to the new medical second use of the above mentioned compound, in which sodium chondroitin sulfate is the most important part of the Agreecan molecule, that induces the regeneration of the cartilage by acting as an artificial matrix. The absence of risks of the compound is proven by the description of the product, which states that it has no side effects reported for its intraocular use.

+ + + + + + + + + + + + + +

Figures 1-15.

REMARKS

Applicant appreciates the time taken by the Examiner to review Applicants' present application and to discuss the condition of the application prior to issuance, relative to the Notice of Allowance mailed August 11, 2004. As discussed with the Examiner, Applicant encloses the following requested documents.

1. A revised specification with Figures 7-15 removed is included. The specification was revised to include appropriate references to the new Figures 7-15 and to correct minor grammatical errors. Figures 7-15 are now included with originally submitted Figures 1-6 and are specifically labeled as Figures 7-15. The application will now consist of Figures 1-15. For the Examiner's convenience we have included a complete set of Figures. Please note that the Examiner already has in his possession Formal Drawings for Figures 1-6. Applicant believes that the new Figures 7-15 will meet the specification of the Patent Office.

2. A copy of the Notice of Allowance and Fee(s) due, mailed August 11, 2004 is included.


3. A copy of Part B - Fee(s) Transmittal submitted to the Patent Office on September 17, 2004.

CONCLUSION

Applicant believes that with the submission of these documents the application is now in condition for issuance. For the foregoing reasons and for other reasons clearly apparent, Applicant respectfully request that a patent be issued.

The Examiner is invited to contact the undersigned by telephone or facsimile if the Examiner believes that such a communication would advance the issuance of the present invention.

Respectfully submitted,


Armando Pastrana, Jr
Registration No. 44,997
Phone No. (817) 615-5056
Facsimile (817) 551-4610

Date

07 FEB 05

Address for Correspondence:

Armando Pastrana, Jr. - Q-148
R&D Counsel
Alcon Research, Ltd.
6201 So. Freeway
Fort Worth, TX 76134-2099
Docket No. 2514F US